A molecule produced by the body's immune system appears to play a key role in killing tumor cells and reducing inflammation, according to a new study.

The molecule, called interferon-gamma (IFN-γ), is produced by a type of white blood cell called a T cell. T cells are part of the immune system's adaptive immune response, which is responsible for recognizing and attacking foreign invaders such as bacteria, viruses, and tumor cells.

IFN-γ has been shown to have a variety of anti-tumor effects, including inhibiting tumor cell growth, promoting tumor cell death, and enhancing the immune system's ability to recognize and attack tumor cells. In addition, IFN-γ has been shown to reduce inflammation, which is a key factor in the development and progression of many types of cancer.

The new study, published in the journal Nature Medicine, provides further evidence for the anti-tumor and anti-inflammatory effects of IFN-γ. In the study, researchers found that IFN-γ was able to induce cell death in a variety of human tumor cell lines, including breast cancer, lung cancer, and colon cancer cells. IFN-γ also reduced inflammation in mouse models of cancer.

The researchers believe that IFN-γ could be a potential new therapy for cancer and other diseases characterized by inflammation. However, further research is needed to determine the optimal dose and schedule of IFN-γ administration, as well as to identify any potential side effects.

"IFN-γ is a promising new therapy for cancer and other diseases characterized by inflammation," said study lead author Dr. John Zhang of the University of Texas MD Anderson Cancer Center. "However, further research is needed to determine the optimal dose and schedule of IFN-γ administration, as well as to identify any potential side effects."